Fact check · Version 1 · Sources checked
“FDA has banned LL-37.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Misleading
This statement leaves out a limit that changes its meaning.
The person or group who asked FDA to consider LL-37 for its pharmacy-compounding list withdrew the request. That request was called a 503A nomination. Its withdrawal is not a ban. The current federal rule does not list LL-37. FDA plans an advisory-committee discussion before the end of February 2027. That discussion is not a final decision or drug approval.
- What this answer is based on
- This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The U.S. pharmacy-compounding status as reviewed August 30, 2026; an advisory discussion is not a final FDA action. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- Whether a specific product has an approval or another official status.
Sources for this fact check
Show 4 sources
01FDA review of safety risks for certain bulk drug substancesU.S. Food and Drug Administration · FDA review · 202602FDA bulk drug substances nominated for compoundingU.S. Food and Drug Administration · Regulatory · 202603Pharmacy Compounding Advisory Committee meeting planningU.S. Food and Drug Administration · Regulatory · 20260421 CFR 216.23 bulk drug substances listElectronic Code of Federal Regulations · Regulatory · 2026
- Sources checked by
- Site editor · Editorial review